Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/phcogcommn/phcogcommn.org/sites/all/modules/biblio/includes/biblio_theme.inc).

A Mini-review of Galactomannas and Diosgenin in Fenugreek

Jan
12
2021
By tahmed

groupview

Abstract
Pharmacognosy Communications,2021,11,1,26-30.
DOI:10.5530/pc.2021.1.6
Published:January 2021
Type:Review Article

A Mini-review of Galactomannas and Diosgenin in Fenugreek

Mohamad Hesam Shahrajabian1, Wenli Sun1, Hong Shen2, Qi Cheng1,3,*

1Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing, CHINA.

2NMPA Key laboratory for Testing and Risk Warning of Pharmaceutical Microbiology, Biological Inspection Department, Zhejiang Institute for Food and Drug Control, Hangzhou, CHINA.

3College of Life Sciences, Hebei Agricultural University, Baoding, Hebei, China; Global Alliance of HeBAU-CLS&HeQiS for BioAI-Manufacturing, Baoding, Hebei, CHINA.

Abstract:

Introduction: Galactomannas are polysaccharides similar to cellulose and starch. Methods: A literature search was conducted in Medline, Scopus, PubMed and Google scholar databases. The keywords were fenugreek, health benefits, bioactive components, galactomannans, diosgenin and pharmaceutical science. Results: Fenugreek galactomannan is a heteropolysaccharide which reduces blood glucose level as normalize the surface activities inside the small intestine. They are also used in food products in order to increase the thickness of the water content. The most important health benefits of galactomanna are reduction in LDL cholesterol levels in hypercholesterolemic, blood lipids, as well as to reduce blood pressure and fibrinolysis. Diosgenin is an isospirostane derivative and the product of acids or enzymes hydrolysis process of dioscin and protodioscin. Conclusion: Diosgenin shows biological activities including antioxidant, anti-diabetes, anti-inflammatory, anti-cancer and anti-adipogenic effects.

Keywords:Bioactive Components, Diosgenin, Fenugreek, Galactomannans, Health Benefits, Pharmaceutical Science

View:

A Mini-review of Galactomannas and Diosgenin in Fenugreek
Tags: 

Cite This Article

Vancouver Style :: Shahrajabian MHesam, Sun W, Shen H, Cheng Q. A Mini-review of Galactomannas and Diosgenin in Fenugreek. Pharmacognosy Communications. 2021;11(1):26-30.  (278.9 KB)
MLA Style: Shahrajabian MHesam, Sun W, Shen H, Cheng Q. A Mini-review of Galactomannas and Diosgenin in Fenugreek. Pharmacognosy Communications. 2021;11(1):26-30.  (278.9 KB)
CSE Style: Shahrajabian MHesam, Sun W, Shen H, Cheng Q. A Mini-review of Galactomannas and Diosgenin in Fenugreek. Pharmacognosy Communications. 2021;11(1):26-30.  (278.9 KB)
APA Style: Shahrajabian MHesam, Sun W, Shen H, Cheng Q. A Mini-review of Galactomannas and Diosgenin in Fenugreek. Pharmacognosy Communications. 2021;11(1):26-30.  (278.9 KB)

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

 

ISSN :2249-0159 (Print) ; 2249-0167 (Online)

Frequency : Quarterly Rapid at a time publication (4 issues/year)

 

 

 

 

Pharmacognosy Communications -an official publication of Phcog.Net and the journals and its contents owned by Phcog.Net are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 4.0 License. Permissions beyond the scope of this license may be available with journals@phcog.net

Copyright 2015-16 Phcog.Net | Publishing partner: EManuscript Services